To develop Padmakadi eye patch and its clinical efficacy study by comparison with conventional Bidalaka for anti-inflammatory activity in Anterior segment diseases of eye.

Development of Padmakadi eye patch and its clinical comparative evaluation with conventional Bidalaka for anti-inflammatory activity in Anterior segment diseases- An open labelled double arm randomised comparative clinical trial. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/04/065834

Enrollment

130

Registered

2024-04-16

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H102- Other acute conjunctivitis

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Acute cases of Conjunctivitis/Epi Scleritis/Subconjunctival haemorrhage / Dry eye with inflammation. 2. Patients without any skin allergies towards exposure of particular materials.

Exclusion criteria

Exclusion criteria: 1. Patients with other anterior eye diseases 2. Patients with dry eye induced corneal denudation 3. Patients with raised IOP greater than 21 mm Hg in Non-contact tonometer or Schiotz tonometry. 4. Patients of dry eye syndrome with corneal staining. 5. Medically unfit for completion of the trial 6. Involvement in another interventional research study

Design outcomes

Primary

Measure	Time frame
•Development of Padmakadi eye patch for inflammatory conditions of anterior segment eye diseases and its anti-inflammatory activity of Padmakadi eye patch (2 times/day) in terms of reduction in Efron grading of bulbar conjunctival redness , CCLRU grading of Bulbar redness scale , VAS scale for ocular pain and follicular grading of palpebral conjunctiva compared to Padmakadi Bidalaka (3 times/day) in classical way for 7 days in patients of anterior segment eye diseases. Timepoint: •after 7 days	—

Measure

Time frame

•Development of Padmakadi eye patch for inflammatory conditions of anterior segment eye diseases and its anti-inflammatory activity of Padmakadi eye patch (2 times/day) in terms of reduction in Efron grading of bulbar conjunctival redness , CCLRU grading of Bulbar redness scale , VAS scale for ocular pain and follicular grading of palpebral conjunctiva compared to Padmakadi Bidalaka (3 times/day) in classical way for 7 days in patients of anterior segment eye diseases. Timepoint: •after 7 days

—

Secondary

Measure	Time frame
• The computational correlation study revealing gene-target interactions among bio-actives in Padmakadi eye patch against anterior segment diseases.Timepoint: baseline	—

Countries

India

Contacts

Public ContactDr Manjusha R

All India Institute of Ayurveda

bhatrajma2008@gmail.com9560788850

Outcome results